ReviewFrontiers in drug delivery2025
Nickel nanoparticles: a novel platform for cancer-targeted delivery and multimodal therapy.
Review in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Nonanuclear Pd-Based Coordination Cage Featuring Ni-Chelated Porphyrin Ligand for Cancer Therapy via Combination of Chemodynamic and Photodynamic Modalities.Molecules (Basel, Switzerland) · 2026Article
- Emerging Approaches for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: The Application of Nanomedicines.International journal of nanomedicine · 2026Review
- Promoting Drp1-Mediated Mitochondrial Division in Nickel Nanoparticles-Induced Reproductive Toxicity in GC-2 Cells.Nanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional cancer treatment methods often encounter limitations, such as poor targeting, low bioavailability, and high systemic toxicity. These challenges have led researchers to explore alternative therapeutic strategies. Nickel nanoparticles (NiNPs), owing to their distinctive physicochemical properties and tunable biocompatibility, have attracted considerable attention in cancer therapy and drug delivery applications. These nanomaterials demonstrate excellent magnetic properties, photothermal conversion capabilities, catalytic activity, and potential for multifunctionality and targeted drug delivery via surface modification. This review highlights recent advancements in the use of NiNPs for cancer treatment, emphasizing their advantages as drug carriers that enhance the bioavailability, targeting, and therapeutic efficacy of anticancer agents. Additionally, the synergistic applications of NiNPs in multimodal therapies, including magnetic hyperthermia, photothermal therapy, and chemodynamic therapy, are discussed, as well as their potential as theranostic platforms. Although nickel-based nanodelivery systems show significant promise for clinical translation, issues related to biosafety, degradation metabolism, and long-term toxicity remain and require further investigation to support their clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.